Mody Kabir, Baldeo Candice, Bekaii-Saab Tanios
Department of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ.
Cancer J. 2018 Jul/Aug;24(4):165-170. doi: 10.1097/PPO.0000000000000328.
Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30% to 50% of patients with primary colon cancer will relapse and die of metastatic cancer. The 5-year survival rate of metastatic colorectal cancer remains disappointing at approximately 10%.Angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. There are currently 4 US Food and Drug Administration-approved antiangiogenic agents for metastatic colorectal cancer. Bevacizumab is the only antiangiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Other antiangiogenic agents include ramucirumab, ziv-aflibercept, and regorafenib. We review the data supporting the use of antiangiogenics in this disease.
结直肠癌是全球第三大常见癌症。约20%的结直肠癌患者在初次诊断时就已出现转移性疾病，约30%至50%的原发性结肠癌患者会复发并死于转移性癌症。转移性结直肠癌的5年生存率仍令人失望，约为10%。血管生成在结直肠癌的肿瘤生长和转移中起着重要作用。目前有4种美国食品药品监督管理局批准的用于转移性结直肠癌的抗血管生成药物。贝伐单抗是美国食品药品监督管理局批准的唯一用于一线治疗转移性结直肠癌的抗血管生成药物。其他抗血管生成药物包括雷莫西尤单抗、Ziv-aflibercept和瑞戈非尼。我们回顾了支持在这种疾病中使用抗血管生成药物的数据。
